Accueil   Diary - News   All news Tollys closes Series A financing of €2.3 million

Tollys closes Series A financing of €2.3 million

 

 

Lyon, France, May 26, 2020 – Tollys, the developer of TL-532, the first synthetic specific agonist of Toll-like receptor 3 (“TLR3”) cancer immunotherapy, today announces the closing of a Series A round of financing totaling €2.3 million ($2.5M). This brings the total amount raised to €6.4M ($6.8M) since the company was founded in 2015. The round was closed on the basis of reaching the preclinical proof-of-concept of TL-532, supporting its development towards clinical trials.

 


Current shareholders and new private investors joined the round. The proceeds will be used to advance the preclinical development of TL-532. Notably, Tollys will use the proceeds to manufacture TL-532 and launch the regulatory safety studies required before entry into clinical trials in bladder cancer by late 2021/early 2022.

 

 

Read the press release